Atlantic Equities upgrades Bristol-Myers Squbb (BMY) to "Neutral" from "Underweight" and sets a...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Atlantic Equities upgrades Bristol-Myers Squbb (BMY) to "Neutral" from "Underweight" and sets a price target of $32.50 after the FDA approved the company's Eliquis anti-clotting drug last week. BMY is +2% at $32.55 premarket.